India’s pharma sector was in the spotlight today (23 June 2026)

India’s pharma sector was in the spotlight today (23 June 2026) as the USFDA sought Indian help to tackle a global cancer‑drug shortage,

Sun Pharma advanced its expansion plans, and a tragic fire hit a pharma plant in Andhra Pradesh. Despite mixed news, pharma stocks like Cipla, Zydus Life, and Alkem Labs gained on strong export sentiment. 💊 Key Developments – Pharma Sector (India) 1. USFDA Seeks Indian Support for Cancer‑Drug Shortage The US Food and Drug Administration has approached Indian manufacturers for ifosfamide, a chemotherapy drug used in testicular, bladder, and lung cancers. The shortage stems from disruptions at Baxter International’s US facility and supply‑chain issues linked to the West Asia conflict. The regulator contacted the Indian Drug Manufacturers’ Association (IDMA) to identify firms capable of supplying the drug immediately. Cipla, Zydus Lifesciences, Alkem Labs, Aurobindo Pharma, and Dr. Reddy’s Labs are expected to benefit from potential export orders. 2. Sun Pharma & Aurobindo Pharma Expansion Sun Pharma is acquiring Innovcare Lifesciences for ₹271 crore in an all‑cash deal to strengthen its nutraceutical and cosmeceutical portfolio. Aurobindo Pharma’s US arm received FTC approval for its $250 million acquisition of Lannett Company, enhancing its complex generics and controlled‑substance portfolio. Both deals are expected to close by July 2026, boosting US earnings and product diversity. 3. NITI Aayog Report on API Dependence India still imports ~65% of Active Pharmaceutical Ingredients (APIs) from China. The report urges a shift toward high‑value pharma manufacturing and industry‑academia collaboration to reduce vulnerability. Economists call for stronger Production Linked Incentive (PLI) schemes to promote biopharmaceuticals, complex generics, and orphan drugs.